This article is more than 5 years old. Information may no longer be current.

Anti-TNF drug helped control chronic CME in small study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Tumor necrosis factor may play a role in chronic cystoid macular edema, and a monoclonal antibody showed efficacy in relieving chronic CME in a small trial, according to a recent report.

Nikos N. Markomichelakis, MD, and colleagues at Athens University assessed the efficacy of infliximab, an anti-tumor necrosis factor (TNF) monoclonal antibody, in 14 eyes of uveitis patients with refractory CME.

All eyes received an intravenous infusion of 5 mg/kg of infliximab. After 1 month, five patients were retreated. Macular thickness was reduced from a mean of 428 µm to a mean of 219 µm at 2 months post-baseline. At 6 months, anatomic and functional improvement was sustained in all eyes, the study authors found.

The study is published in the American Journal of Ophthalmology.